Management

Jennifer Jarrett is Chief Executive Officer of Damora Therapeutics. She is a seasoned executive with nearly three decades of experience in corporate strategy, finance and investor relations, drug development, and organizational leadership. Most recently, she served as Chief Operating Officer of Arcus Biosciences, a development-stage oncology company. During her tenure, she also served as Chief Financial Officer and a member of the company’s Board of Directors. Prior to Arcus, Ms. Jarrett served as Vice President of Corporate Development and Capital Markets at Uber Technologies, Inc. Previously, she was Chief Financial Officer of Medivation, a commercial oncology company that developed the blockbuster medicine XTANDI® (enzalutamide) for prostate cancer, through the company’s acquisition by Pfizer. Ms. Jarrett spent 20 years in investment banking, including at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett received a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business. She serves on the boards of Sagimet Biosciences, Syndax Pharmaceuticals and Zura Bio.

Sherwin Sattarzadeh is Chief Operating Officer of Damora Therapeutics. He brings over 20 years of industry experience across the many facets and stages of drug development and company lifecycle. Most recently, Mr. Sattarzadeh served as Chief Business Officer at Blueprint Medicines. During his 10 years at Blueprint Medicines, he held positions of increasing responsibility, including Head of Regulatory Affairs, Chief of Staff, and SVP Strategic Operations. He has an extensive background in hematology/oncology and rare disease drug development, having led and contributed to the global approvals of AYVAKIT® (avapritinib), GAVRETO® (pralsetinib), CERDELGA® (eliglustat), and MOZOBIL® (plerixafor). Mr. Sattarzadeh received his M.B.A. from Boston University and holds a B.Sc. in Chemistry from the University of British Columbia.

Dr. Becker Hewes is Chief Medical Officer of Damora Therapeutics. Dr. Hewes brings over two decades of experience in drug development in public biotechnology companies. Most recently, he served as Chief Medical Officer at Blueprint Medicines. During his time at Blueprint Medicines, Dr. Hewes led the development of an industry-leading pipeline across mast cell disorders and solid tumors, including the approval of AYVAKIT (avapritinib) for indolent and advanced systemic mastocytosis. Prior to joining Blueprint Medicines, he had an illustrious career in hematology/oncology drug development, having led clinical development and translational medicine efforts for multiple early-stage oncology programs through clinical proof-of-concept, including Kisqali® (ribociclib), as well as leading registration programs for Bosulif® (bosutinib), and Torisel® (temsirolimus). Dr Hewes received his BS from Vanderbilt University and an M.D. from Georgetown University. He completed his residency at New York Hospital/Cornell Medical Center and his fellowship training in Pediatric Oncology at Emory University.

Jim Baker is Chief Corporate Affairs Officer of Damora Therapeutics. He brings 20 years of experience building entrepreneurial, science-driven companies from discovery to commercialization. Previously, Mr. Baker was Senior Vice President, Corporate Affairs at Blueprint Medicines, where he oversaw investor relations, corporate communications, patient affairs, internal communications and public policy for nearly a decade until the company’s acquisition by Sanofi. Over this time, he played a key role in guiding the company’s evolution from an early development-stage enterprise to a fully integrated global biotech company with two marketed medicines. This included helping the company raise more than $1.5 billion in capital, globally launch the blockbuster product AYVAKIT® (avapritinib), advance innovative R&D in allergy/inflammation, oncology and rare disease, and maintain a high-performance culture through significant growth and change. Prior to joining Blueprint, Mr. Baker held roles in investor relations, corporate communications, new product planning and market development, and patient advocacy at Biogen, Sarepta Therapeutics, PTC Therapeutics, and Idera Pharmaceuticals. He began his career with B.A. degrees in journalism and political science from the University of Southern California, where he was a Reserve Officer Training Corps scholar, and completed his military service as a Captain in the U.S. Army Signal Corps.

Garrett Winslow brings more than 15 years of experience working with public companies in the life sciences industry. He previously served as the General Counsel of Galecto, Inc. and Spring Bank Pharmaceuticals, publicly listed clinical-stage biotechnology companies. Prior to that, he was a partner in the Corporate and Securities group at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in Boston, Massachusetts, where he advised public and private companies on securities law compliance, corporate governance and transactional matters. Mr. Winslow received his Master’s in Taxation from Boston University Law School, J.D. degree from Suffolk University Law School and B.A. degree in Business Administration from the University of Washington.

Brian Burkavage is Senior Vice President, Finance and Chief Accounting Officer of Damora Therapeutics. Previously, Mr. Burkavage served as Senior Vice President, Finance and Chief Accounting Officer at IO Biotech. Prior to that, he served as the Controller at Passage Bio and Director of Financial Planning and Analysis at Aclaris Therapeutics. Earlier in his career, he spent more than a decade at Ernst & Young LLP in roles of increasing responsibility within the financial statement audit practice. Mr. Burkavage earned his B.A. and M.S.A. from the University of Notre Dame and is a licensed Certified Public Accountant.